Found 2 hits in this display Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Neuropeptide Y receptor type 2
(Homo sapiens (Human)) | BDBM50254336
(CHEMBL4092494)Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(CC1CCCCC1)NC(=O)C(CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C(C)(C)NC(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C83H144N28O19/c1-44(2)35-56(74(126)110-83(7,8)78(130)109-64(45(3)113)76(128)101-52(28-19-33-95-80(89)90)66(118)100-54(30-31-62(84)115)69(121)99-51(27-18-32-94-79(87)88)67(119)102-55(65(86)117)36-47-21-12-9-13-22-47)103-73(125)60(40-63(85)116)107-71(123)58(38-49-25-16-11-17-26-49)104-70(122)57(37-48-23-14-10-15-24-48)105-72(124)59(39-50-41-93-43-97-50)106-68(120)53(29-20-34-96-81(91)92)108-77(129)82(5,6)111-75(127)61(42-112)98-46(4)114/h41,43-45,47-49,51-61,64,112-113H,9-40,42H2,1-8H3,(H2,84,115)(H2,85,116)(H2,86,117)(H,93,97)(H,98,114)(H,99,121)(H,100,118)(H,101,128)(H,102,119)(H,103,125)(H,104,122)(H,105,124)(H,106,120)(H,107,123)(H,108,129)(H,109,130)(H,110,126)(H,111,127)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t45-,51+,52+,53+,54+,55?,56+,57?,58?,59+,60+,61+,64+/m1/s1 | PDB
Reactome pathway
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2 | n/a | n/a | n/a | n/a | n/a | n/a |
Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan.
Curated by ChEMBL
| Assay Description
Displacement of [125I]-PYY from human Y2R expressed in CHO cell membranes after 60 mins by liquid scintillation method |
ACS Med Chem Lett 8: 628-631 (2017)
Article DOI: 10.1021/acsmedchemlett.7b00047
BindingDB Entry DOI: 10.7270/Q2W37ZS8 |
More data for this
Ligand-Target Pair | |
Neuropeptide Y receptor type 2
(Homo sapiens (Human)) | BDBM50254336
(CHEMBL4092494)Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(CC1CCCCC1)NC(=O)C(CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C(C)(C)NC(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C83H144N28O19/c1-44(2)35-56(74(126)110-83(7,8)78(130)109-64(45(3)113)76(128)101-52(28-19-33-95-80(89)90)66(118)100-54(30-31-62(84)115)69(121)99-51(27-18-32-94-79(87)88)67(119)102-55(65(86)117)36-47-21-12-9-13-22-47)103-73(125)60(40-63(85)116)107-71(123)58(38-49-25-16-11-17-26-49)104-70(122)57(37-48-23-14-10-15-24-48)105-72(124)59(39-50-41-93-43-97-50)106-68(120)53(29-20-34-96-81(91)92)108-77(129)82(5,6)111-75(127)61(42-112)98-46(4)114/h41,43-45,47-49,51-61,64,112-113H,9-40,42H2,1-8H3,(H2,84,115)(H2,85,116)(H2,86,117)(H,93,97)(H,98,114)(H,99,121)(H,100,118)(H,101,128)(H,102,119)(H,103,125)(H,104,122)(H,105,124)(H,106,120)(H,107,123)(H,108,129)(H,109,130)(H,110,126)(H,111,127)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t45-,51+,52+,53+,54+,55?,56+,57?,58?,59+,60+,61+,64+/m1/s1 | PDB
Reactome pathway
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.550 | n/a | n/a | n/a | n/a |
Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan.
Curated by ChEMBL
| Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method |
ACS Med Chem Lett 8: 628-631 (2017)
Article DOI: 10.1021/acsmedchemlett.7b00047
BindingDB Entry DOI: 10.7270/Q2W37ZS8 |
More data for this
Ligand-Target Pair | |